Novartis lung cancer drug gets priority U.S. review

Novartis has won fast-track U.S. regulatory review for capmatinib (INC280) in a hard-to-treat form of lung cancer, the Swiss drugmaker said on Tuesday.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news